Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus

Tan, Hong Chang; Tai, E. Shyong; Sviridov, Dmitri; Nestel, Paul J.; Ng, Cindy; Chan, Edmund; Teo, Yvonne; Wai, D.C.H.

doi:10.1016/j.jacl.2011.06.016

Cited by 34 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies measured the efflux using ApoB deleted plasma as a HDL-enriched acceptor medium [11,14], adjusting plasma at 2.0-2.8% volume of the obtained fraction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes

Murakami

Tanabe

Tamasawa

et al. 2013

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Recent studies measured the efflux using ApoB deleted plasma as a HDL-enriched acceptor medium [11,14], adjusting plasma at 2.0-2.8% volume of the obtained fraction.…”

Section: Discussionmentioning

confidence: 99%

“…All of these properties contribute to the antiatherogenic activities of HDL. However, the function of HDL has not been studied in depth [13,14], except for static measurement of blood levels of HDL-cholesterol and ApoA-I [15,16].…”

Section: Introductionmentioning

confidence: 99%

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes

Murakami

Tanabe

Tamasawa

et al. 2013

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…A function of HDL accepted to be of benefit to vascular health is the ability to extract cellular cholesterol and facilitate reverse cholesterol transport (RCT), a multi-step, multi-organ process that shuttles excess tissue cholesterol to the liver for excretion in bile (36,37). Modulation of the first step in RCT, namely, cholesterol efflux, can affect atherosclerotic plaque burden and composition (37–40).…”

Section: Introductionmentioning

confidence: 99%

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein

Kon¹,

Yang²,

Fazio³

2015

Archives of Medical Research

View full text Add to dashboard Cite

Although reducing low-density lipoprotein-cholesterol (LDL-C) levels with lipid-lowering agents (statins) decreases cardiovascular disease (CVD) risk, a substantial residual risk (up to 70% of baseline) remains after treatment in most patient populations. High-density lipoprotein (HDL) is a potential contributor to residual risk, and low HDL-cholesterol (HDL-C) is an established risk factor for CVD. However, in contrast to conventional lipid-lowering therapies, recent studies show that pharmacologic increases in HDL-C levels do not bring about clinical benefits. These observations have given rise to the concept of dysfunctional HDL where increases in serum HDL-C may not be beneficial because HDL loss of function is not corrected by or even intensified by the therapy. Chronic kidney disease (CKD) increases CVD risk, and patients whose CKD progresses to end-stage renal disease (ESRD) requiring dialysis are at the highest CVD risk of any patient type studied. The ESRD population is also unique in its lack of significant benefit from standard lipid-lowering interventions. Recent studies indicate that HDL-C levels do not predict CVD in the CKD population. Moreover, CKD profoundly alters metabolism and composition of HDL particles and impairs their protective effects on functions such as cellular cholesterol efflux, endothelial protection, and control of inflammation and oxidation. Thus, CKD-induced perturbations in HDL may contribute to the excess CVD in CKD patients. Understanding the mechanisms of vascular protection in renal disease can present new therapeutic targets for intervention in this population.

show abstract

“…Although HDL-C is correlated to HDL-P, the relation of HDL-C with CVD is complex, influenced by atherogenic lipoproteins, inflammation, and insulin resistance, making it a poorer marker in those with DM. 16 In fact, in those with DM, HDL-P but not HDL-C is associated with cholesterol efflux 17 and that prediction of CHD by HDL-C may be explained by markers associated with MetS. 18 This was not the case for HDL-P, which was also predictive of CHD and remained predictive after additional adjustments for apolipoprotein B and triglycerides.…”

mentioning

confidence: 99%

Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])

Tehrani

Zhao

Blaha³

et al. 2016

The American Journal of Cardiology

View full text Add to dashboard Cite

Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus

Cited by 34 publications

References 37 publications

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein

Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])

Contact Info

Product

Resources

About